唑吡坦
医学
临床试验
重症监护医学
人口
内科学
精神科
失眠症
环境卫生
作者
Caleb Smack,Katherine Johnson,Noah Meester,Leah Shelton,Namrata Singh
出处
期刊:Clinical Neuropharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-01
卷期号:47 (2): 59-61
标识
DOI:10.1097/wnf.0000000000000587
摘要
Objective In this report, we discuss the case of a patient with minimally conscious state (MCS) whose clinical condition significantly improved after Zolpidem therapy. We aim to provide supportive evidence for inclusion of zolpidem trials in patients with MCS. Methods Our team used electronic medical records, direct patient care experiences, and literature review to obtain information for this case report. Results Twice daily zolpidem therapy led to significant clinical improvement in our patient with MCS. In addition, this improvement was maintained throughout an increasingly arduous medical course. Conclusions Minimally conscious state is a disorder with limited proven therapeutic options. Zolpidem administration has demonstrated immense benefit in a select population of patients, including ours. Given the potential for great improvement with limited downside, zolpidem trial presents an intriguing treatment option. Further clarification of prognostic features to stratify responders and nonresponders to therapy is needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI